Studies assessing sexual dysfunction in type 2 diabetic women are scanty. This study was designed to evaluate the prevalence and correlates of female sexual function in a quite large population of diabetic women. A total of 595 women with type 2 diabetes completed a questionnaire of self-report measures of sexual dysfunction and were analyzed in this study. Their age was 57.9 ± 6.9 (mean and s.d.), duration of diabetes was 5.2 ± 1.5 years and mean hemoglobin A1c (HbA1c) level was 8.3±1.3%. Female sexual dysfunction (FSD) was assessed by the Female Sexual Function Index instrument with a cut-off score of 23. The overall prevalence of FSD among the diabetic women was 53.4%, significantly higher in menopausal women (63.9%), as compared with nonmenopausal women (41.0%, Po0.001). There was no association between HbA1c, duration of diabetes, hypertension, or cigarette smoking status and FSD; on the contrary, age, metabolic syndrome and atherogenic dyslipidemia were significantly associated with FSD. Both depression and marital status were independent predictors of FSD, while physical activity was protective. Further studies are needed to elucidate in full the mechanisms underlying the evident differences between male and female sexual function. In the meantime, evaluation of female sexuality should become a routine evaluation in women with type 2 diabetes, such as other diabetic complications.
Introduction
Female sexual dysfunction (FSD) is a common problem worldwide. [1] [2] [3] An international survey of 13 882 women 40-80 years of age found that 39% of sexually active women reported at least one problem with sexual activity. 4 Diabetes has long been considered a major cause of impaired sexual function in men, with prevalence rates of ED approaching 50% in both type 1 and type 2 diabetes. 1, 5, 6 Although diabetic women suffer from the same vascular and neurological complications thought to be instrumental for the occurrence of sexual dysfunction in diabetic men, results of sexual functioning of women with diabetes are less conclusive. [7] [8] [9] [10] [11] [12] Inaccurate or inadequate characterization of diabetes, including glycemic control and neurovascular complications, and the coexistence of depression may be implicated. In spite of these limitations, most studies have found a higher prevalence of FSD in diabetic women as compared with nondiabetic women. [12] [13] [14] [15] [16] Recent studies focused the attention on type 1 diabetic women, probably because type 1 diabetes may be free, at least for many years of its natural history, of metabolic risk factors that are associated with FSD, 17, 18 this might have offered the unique opportunity to examine the role of diabetes per se, independent of associated comorbidities, on sexual function. So far, a high prevalence of sexual dysfunction has been reported in type 1 diabetic women, including loss of desire, lubrication difficulties, dyspaurenia and loss of the ability to reach orgasm. 19 However, and in apparent contrast with diabetic men, no association was found between sexual dysfunction and cardiovascular, metabolic, and other risk factors, such as age, body mass index (BMI), menopause and use of hormone replacement therapy. 7 It seems that in type 1 diabetes sexual dysfunction is related more directly to psychological factors, 14 an interpretation recently confirmed by the results of a large prospective study of 625 women with type 1 diabetes (Epidemiology of Diabetes Interventions and Complications study), in which depression was found to be the major predictor of sexual dysfunction. 17 A somewhat different picture seems to emerge from the results of studies evaluating sexual dysfunction in type 2 diabetic women: although the findings may be considered preliminary given the paucity of studies and the small samples analyzed, determinants of sexual function in type 2 diabetic women may include age, duration of diabetes, vascular complications and menopause. [13] [14] [15] [16] This study was designed to evaluate the prevalence and correlates of female sexual function in a population of diabetic women. The Campanian Post-Prandial Hyperglycemia Study 20, 21 provided the opportunity to evaluate FSD in the context of a large observational study of type 2 diabetic patients.
Materials and methods

Participants
The rationale and preliminary data of the ongoing CAPRI (CAmpanian post-PRandIal hyperglycemia group) study have been published. 20, 21 Consecutive patients with type 2 diabetes were recruited among outpatients regularly attending Diabetes Clinics located in the area of the Campania County, South Italy, from 2001. Inclusion criteria for the initial selection of patients were: a diagnosis of type 2 diabetes for at least 6 months but o10 years, age 35-70 years, BMI of 24 or higher, hemoglobin A1c (HbA1c) of 6.5% or higher, treatment with diet or oral drugs. Criteria for exclusion were: need for insulin use, concomitant chronic diseases, including kidney, liver and cardiovascular diseases, recent acute illness, or change in diet, treatment or lifestyle within the 3 months before the initial assessment. The study was approved by the Institutional Committee of Ethical Practice of our institution, and all women gave informed written consent.
After the initial screening visit, with verification of inclusion and exclusion criteria, patients were invited to follow their usual treatment and eat their usual diet during the month. All patients were invited to the reference center (Department of Geriatrics and Metabolic Diseases at the Second University of Naples) for blood sampling and any other centralized assessment. A total of 1270 patients (611 men and 659 women) were invited to complete a food-frequency questionnaire, as well as self-report measures of sexual dysfunction and urological complications (that is, bladder dysfunction and urinary tract infections). A total of 595 (90.2%) of the 659 women completed both questionnaires and were analyzed in the preset study.
Assessment of sexual function
We used the validated, 19 items self-report instrument for assessing key dimensions of female sexual function, as previously described by Rosen et al., 22 with a total of six domains being analyzed. Specific domains analyzed in the Female Sexual Function Index (FSFI) included: desire, arousal, lubrication, orgasm, satisfaction and pain. Each domain was scored on a scale of 0 or 1-6, with higher score indicating better function. For each six domains, a score was calculated and the total score was obtained by adding the six domain scores. The total score range was 2-36. A cut-off FSFI full-scale score of 26 or less is currently being accepted for diagnosis of sexual dysfunction in women within a wide age range (18-74 years). 23 However, this cut-off point may give rates of sexual dysfunction ranging from 22 to 50% in fertile women, 24 leading to the poor likelihood that the majority of fertile healthy women in their forties should be at risk for sexual dysfunction. So, we decided to include a more conservative measure of sexual function based on the percentage of women falling below the lower quartile of distribution of the FSFI full-scale score for premenopausal women not using oral contraception. The FSFI cut-off score was set at 23 based on the results of a recent Italian study assessing sexual function in healthy women attending a gynecological office, 25 and also on our previous data. 18 The lower quartile of distribution in our control population was 22.9 (upper quartile 31.5, median 28.9), which was considered pertinent with a cut-off point of 23.
In this study, the prevalence of depression was based on patient self-report of use of antidepressant medications and/or psychological counseling for depressive symptoms.
Anthropometric measures and laboratory analyses
Height and weight were measured to the nearest 0.5 cm and 100 g, respectively, with participants wearing lightweight clothing and no shoes. BMI was calculated as weight (in kilograms) divided by standing height (in meters squared). Arterial blood pressure was measured three times, at the end of the physical examination with the subject in sitting position. Before blood pressure evaluation all participants were at least 15 min at rest. Patients whose average blood pressure levels were greater or equal to 140/90 mm Hg or who were under antihypertensive medication were classified as hypertensive. Waist-to-hip ratio was calculated as the waist circumference in centimeters divided by the hip circumference in centimeters. The diagnosis of the metabolic syndrome was carried out as recommended by the Adult Treatment Panel III for women: 26 (1) abdominal adiposity as defined by a waist circumference 488 cm; (2) low serum high-density lipoprotein-cholesterol (o50 mg per 100 ml); (3) high triglyceride levels (X150 mg per 100 ml); (4) elevated blood pressure as defined by a blood pressure of at least 130/85 mm Hg; and (5) abnormal glucose homeostasis as defined by a fasting plasma glucose concentration of X110 mg FSD in type 2 diabetes K Esposito et al per 100 ml. The presence of at least three of the above criteria qualified women for the diagnosis of metabolic syndrome. Atherogenic dyslipidemia was defined as the combination of triglycerides levels 4200 mg per 100 ml and high-density lipoproteincholesterol levels o50 mg per 100 ml. 27 For the ascertainment of physical activity status, we used the International Physical Activity Questionnaire, 28 as an index of weekly energy expenditure using frequency (times per week), duration (in minutes per time) and intensity of sports or other habits related to physical activity. Participants who did not report any physical activities were defined as sedentary. Physical activity was computed in metabolic equivalent tasks per week.
Laboratory assessment was centralized. Blood glucose and serum lipids were measured by enzymatic assays in the hospital's chemistry laboratory, HbA1c by nephelometry and serum insulin by radioimmunoassay (Pharmacia, Milan, Italy). The interassay coefficient of variation was below 6% for all measurements. Fasting glucose is the mean of the two home blood glucose assessments.
Statistical analysis
Descriptive statistics were used to characterize the study sample. w 2 was used for trend test, and Kruskall-Wallis test for comparison of numeric variables without normal distribution. Multivariate analyses were used to characterize the association between the usual risk factors for FSD while adjusting for covariates. Forward logistic regression models were tested, including FSD status as a dependent variable in the model. Correlation analyses were used to assess and control for the effect of collinearity. The final model was tested by means of the Holmer and Lemeshow goodness-of-fit test. All statistical analyses were performed using SPSS software (version 10.05, SPSS, Chicago, IL, USA).
Results
A total of 595 women completed the questionnaires. The sample who completed the survey did not differ on the variables at baseline compared with the 64 women who did not participate in the study. Table 1 shows the demographic and clinical characteristics of the study population. A majority of the diabetic patients had HbA1c level higher than 7% and are considered out of good glycemic control according to recent guidelines. 29 The prevalence of obesity (BMI 430), metabolic syndrome, hypertension and atherogenic dyslipidemia was 29.4, 70.0, 53.9 and 19.7%%, respectively.
The characteristics of sexual function in the sample of type 2 diabetic women are shown in Table 2 . On the basis of the FSFI cut-off score for sexual dysfunction of 23, the overall prevalence of FSD among the diabetic women of this study was found to be 53.4%. Specifically, the prevalence of FSD was significantly higher (63.9%) in menopausal women as compared with nonmenopausal women (41.0%); for most sexual domains, there was no significant difference between groups, except for lubrication which was significantly lower in menopausal women.
The contribution of age, HbA1c, duration of diabetes, anthropometric characteristics, prevalence of obesity, metabolic syndrome, hypertension, atherogenic dyslipidemia, smoking status, physical activity, depression and marital status to risk of FSD, based on multivariate logistic regression, is shown in Table 3 . There was no association between HbA1c, duration of diabetes, hypertension, or cigarette smoking status and FSD; there was an association between BMI and FSD. On the contrary, age, metabolic syndrome and atherogenic dyslipidemia were significantly associated with FSD. When controlling for the effects of other variables, both depression and marital status were independent predictors of FSD: women with type 2 diabetes who has signs of depression were 1.86 times more likely 
Discussion
The aim of this study was the evaluate the prevalence and risk factors associated with FSD in a population of type 2 diabetic women using a validated measure of sexual function. The large sample size (N ¼ 595), the wide range of women's age (35-70 years) and the possibility to dissect the effect of menopause represent distinctive characteristics of this study. The overall FSD prevalence rate in our study was approximately 54%, which is higher than that reported in younger women with type 1 diabetes (up to 35%). 12 The studies that until now addressed FSD in women with type 2 diabetes suffer most from small sample size: 13, 14, 16, 30, 31 in all these studies sample size was well below 100 diabetic patients (range 30-72 women), and all studies reported a higher prevalence of FSD in diabetic women as compared with matched nondiabetic women. In the largest study so far published, Abu Ali et al. 15 evaluated 613 diabetic women and 524 nondiabetic women in Jordan, and found a prevalence of FSD of 59.6% in diabetic women 50 years of age or older as compared with 45.6% found in the age-matched nondiabetic women (Po0.05). It is noteworthy that the prevalence of FSD in the diabetic sample aged o50 years was around 41%; mean FSFI score was 20.8. The FSFI scores recorded in other studies were 29.3 (72 women), 13 20.5 (51 women), 14 23.6 (23 women) 16 31 These findings are in line with our results.
Although both sexes share a similar risk of cardiovascular and neurological complications of diabetes, which presumably may arise from similar pathogenetic mechanisms, the pattern of specific effects of diabetes may be different on men and women. ED in diabetic men is associated with glycemic control and other classic cardiovascular and neuropathic complication of diabetes; 1,2,9 moreover, the prevalence of other cardiovascular risk factors (obesity, hypertension, dyslipidemia) is high, especially in type 2 diabetes. Moreover, ED is an independent risk factor for new onset of cardiovascular disease and a powerful predictor of development of major cardiovascular events in diabetic patients with known coronary artery disease. 32, 33 In contrast, FSD in women with type 1 diabetes seems for the most unrelated to cardiovascular risk factors: neuropathy, 34 vascular impairment 12 and psychological complaints 9, 12 have been implicated in the pathogenesis of decreased libido, low arousability, decreased vaginal lubrication, orgasmic dysfunction and dyspaurenia among diabetic women. Even lees defined are the determinants of sexual function in type 2 diabetic women; according to the results of small studies 13, 14, 16, 31 these determinants may include age, duration of diabetes, vascular complications and presence of menopause or psychological morbidity. In our study, FSD did correlate with age, although did not correlate with long-term glycemic control, as assessed by HbA1c level, indicating that the sexual response in women with diabetes is more likely to be affected by other metabolic factors than by merely glucose control. In our study, the presence of metabolic syndrome and atherogenic dyslipidemia were independent predictors of FSD in women with type 2 diabetes, although in absolute terms both depression status and marital status are the most strongly correlated with FSD. From a general point of view, it seems that in both type 1 and type 2 diabetic women psychological factors have a significant role in the development of sexual dysfunction. This view is also consistent with the current thought that female sexuality is largely dependent on psychological and cultural factors than male sexuality.
The results of our study should be interpreted in the context of several possible limitations. Its crosssectional nature does not allow us to make inference regarding cause and effect. As in most epidemiological studies, the potential for residual confounding by uncontrolled covariates is possible. Another limitation is the lack of nondiabetic control group of women; this however, may not be a serious limitation as the level of FSFI score in our study appears to be not dissimilar to that found in the other published studies. Major strengths of this study include the use of validated measures of sexual dysfunction, and the relatively large number of subjects investigated.
In conclusion, women with type 2 diabetes are at risk for several sexual dysfunctions. Glycemic control was not associated with FSD risk; independent predictors of FSD were age, metabolic syndrome and atherogenic dyslipidemia. Depression and marital status are the main independent risk factors for ED. Higher level of physical activity was protective for FSD in our population. Further studies are needed to elucidate in full the mechanisms underlying the evident differences between male and female sexual function. In the meantime, evaluation of female sexuality should become a routine evaluation in type 2 diabetic women, such as other diabetic complications.
